Spruce Biosciences (SPRB) Operating Margin (2023 - 2024)
Spruce Biosciences (SPRB) posted quarterly Operating Margin of 3453.95% for Q4 2024, down 306898.0% year-over-year from N/an in Q1 2024, and down 120.28% quarter-over-quarter from 1568.0% in Q3 2024.
Spruce Biosciences (SPRB) Operating Margin (2023 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported Operating Margin for 2 consecutive years, with 3453.95% the latest figure, recorded in Q4 2024.
- In Q4 2024, Operating Margin fell 306898.0% year-over-year to 3453.95%; the TTM figure through Sep 2025 stood at 7100.0% (down 649183.0% YoY), while the FY2024 annual figure was 1143.37%, down 62859.0% from the prior year.
- Operating Margin retreated to 3453.95% in Q4 2024 per SPRB's latest filing, from 1568.0% in the prior quarter.
- Across five years, Operating Margin topped out at 384.97% in Q4 2023 and bottomed at 3453.95% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,453.95% |
| Sep 30, 2024 | -1,568.00% |
| Jun 30, 2024 | -623.35% |
| Mar 31, 2024 | -631.65% |
| Dec 31, 2023 | -384.97% |
| Sep 30, 2023 | -444.45% |
| Jun 30, 2023 | -635.09% |
| Mar 31, 2023 | -659.95% |